Metsera (MTSR) issued the following statement in response to litigation filed against the Company by Pfizer (PFE): “Pfizer is trying to litigate its way to buying Metsera for a lower price than Novo Nordisk (NVO). Metsera’s Board of Directors will continue to stand firm on behalf of shareholders and patients. Pfizer’s litigation arguments are nonsense, and Metsera will address them in court.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- Pfizer Could Call on Best Buddy Trump to Help Win $8.5B Novo Nordisk Bidding War
- Metsera ‘disagrees with the allegations in Pfizer’s complaint’
- Pfizer (PFE) Sues Metsera and Novo Nordisk Over Disputed Obesity Drug Merger
- Pfizer files lawsuit against Metsera, Novo Nordisk for breach of merger pact
- Pfizer receives early clearance from FTC for Metsera acquisition